Methotrexate for 2000 FIGO low-risk gestational trophoblastic neoplasia patients: efficacy and toxicity

American Journal of Obstetrics and Gynecology

Volumn 200, Issue 6, 2009, Pages 643.e1-643.e6

  Chalouhi, Gihad Elias ^a,b   Golfier, François ^a,b,c   Soignon, Pauline ^a,b   Massardier, Jerome ^a,b,c   Guastalla, Jean Paul ^e   Trillet Lenoir, Veronique ^a,b,c   Schott, Anne Marie ^a,b,d   Raudrant, Daniel ^a,b,c  

^a UNIVERSITÉ DE LYON   (France)

^b HÔTEL DIEU   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e CENTRE LÉON BÉRARD   (France)

Author keywords

2000 International Federation of Gynecology and Obstetrics scoring; efficacy; low risk gestational trophoblastic neoplasia; methotrexate; toxicity

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; FOLINIC ACID; METHOTREXATE; VINCRISTINE;

ADULT; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER CLASSIFICATION; CANCER REGRESSION; CANCER RESISTANCE; CANCER STAGING; CONTROLLED STUDY; CURETTAGE; DISEASE FREE INTERVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; FEMALE; FRANCE; HUMAN; MAJOR CLINICAL STUDY; METABOLIC DISORDER; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; SCORING SYSTEM; TROPHOBLASTIC TUMOR;

ADOLESCENT; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; FEMALE; GESTATIONAL TROPHOBLASTIC NEOPLASMS; HUMANS; METHOTREXATE; MIDDLE AGED; PREGNANCY; RISK FACTORS; YOUNG ADULT;

EID: 67349181028     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2009.03.011     Document Type: Article

References (43)

1. Tonanont M., Inthasorn P., Boriboonhirunsarn D., et al. Response to initial treatment of low and intermediate risk gestational trophoblastic disease with methotrexate and folinic acid. J Med Assoc Thai 88 (2005) 1349-1354
2. Altieri A., Franceschi S., Ferlay J., et al. Epidemiology and etiology of gestational trophoblastic diseases. Lancet Oncol 4 (2003) 670-678
3. Mahajan N.N., Soni R.N., and Mahajan K.N. Comment on single-dose methotrexate regimen in the treatment of low-risk gestational trophoblastic neoplasia. Am J Obstet Gynecol 197 (2007) 325
4. Ngan S., and Seckl M.J. Gestational trophoblastic neoplasia management: an update. Curr Opin Oncol 19 (2007) 486-491
5. Bagshawe K.D. Trophoblastic reminiscences. J Reprod Med 51 (2006) 849-854
6. Golfier F., Frappart L., Schott A.M., et al. A plea for the creation of trophoblastic disease reference centers in France. J Gynecol Biol Reprod (Paris) 29 (2000) 538-547
7. FIGO Oncology Committee. The FIGO staging for gestational trophoblastic neoplasia 2000: FIGO committee report. Int J Gynaecol Obstet 77 (2002) 285-287
8. Ngan H.Y., Bender H., Benedet J.L., et al. Gestational trophoblastic neoplasia, FIGO staging and classification. Int J Gynaecol Obstet 83 (2003) 175-177
9. Li M.C., Hertz R., and Spencer D.B. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med 93 (1956) 361-366
10. Sekharan P.K., Sreedevi N.S., Radhadevi V.P., et al. Management of postmolar gestational trophoblastic disease with methotrexate and folinic acid: 15 years of experience. J Reprod Med 51 (2006) 835-840
11. Osborne R., and Gerulath A. What is the best regimen for low-risk gestational trophoblastic neoplasia?. A review. J Reprod Med 49 (2004) 602-616
12. Honig A., Rieger L., Kristen P., et al. A case of metastasizing invasive hydatidiform mole. Is less-less good?. Review of the literature with regard to adequate treatment. Eur J Gynaecol Oncol 26 (2005) 158-162
13. Karen C., Yong H., Kar Fai T., et al. Single-dose methotrexate regimen in the treatment of low-risk gestational trophoblastic neoplasia. Am J Obstet Gynecol 195 (2006) 1282-1286
14. Gerulath A.H., Ehlen T.G., Bessette P., et al. Gestational trophoblastic disease. J Obstet Gynaecol Can 24 (2002) 434-446
15. Gilani M.M., Yarandi F., Eftekhar Z., et al. Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low-risk gestational trophoblastic neoplasia. Aust N Z J Obstet Gynaecol 45 (2005) 161-164
16. Foulmann K., Guastalla J.P., Caminet N., et al. What is the best protocol of single-agent methotrexate chemotherapy in nonmetastatic or low-risk metastatic gestational trophoblastic tumors?. A review of the evidence. Gynecol Oncol 102 (2006) 103-110
17. Bagshawe K.D., Dent J., Newlands E.S., et al. The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumors (GTT). Br J Obstet Gynaecol 96 (1989) 795-802
18. Van Trommel N.E., Ngo Duc H., Massuger L.F., et al. Early identification of persistent trophoblastic disease with serum hCG concentration ratios. Int J Gynecol Cancer 18 (2008) 318-323
19. Lu W.G., Ye F., Shen Y.M., et al. EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients. Int J Gynecol Cancer 18 (2008) 357-362
20. Kohorn E.I., and Ngan H.Y.S. Staging and classification and clinical practice guidelines of gynecologic cancers. In: Benedet H., Hacker N.F., and Ngan H.Y.S. (Eds). Trophoblastic diseases. Revised (October 2006)
21. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, Version 3.0, Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), March 31, 2003. http://ctep.cancer.gov Accessed July 28, 2008
22. El Amrani M., Aidi S., and Amarenco P. Cerebral ischemic events and anti-cancer therapy. Rev Neurol 159 (2003) 371-380
23. Wenzel L., Berkowitz R.S., Newlands E., et al. Quality of life after gestational trophoblastic disease. J Reprod Med 47 (2002) 387-394
24. McNeish I.A., Strickland S., Holden L., et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol 1 (2002) 1838-1844
25. Srisomboon J., Suprasert P., Phongnarisorn C., et al. Treatment results of methotrexate and folinic acid as primary chemotherapy for nonmetastatic gestational trophoblastic neoplasia. J Med Assoc Thai 88 (2005) 886-890
26. Van Trommel N.E., Massuger L.F., Schijf C.P., et al. Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic disease. J Clin Oncol 24 (2006) 52-58
27. Berkowitz R.S., Goldstein D.P., and Bernstein M.R. Ten year's experience with methotrexate and folic acid as primary therapy for gestational trophoblastic disease. Gynecol Oncol 23 (1986) 111-118
28. Lara F.M., Alvarado A.M., Candelaria M., et al. Gestational trophoblastic disease: experience at National Institute of Cancerology. Ginecol Obstet Mex 73 (2005) 308-314
29. Khan F., Everard J., Ahmed S., et al. Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects. Br J Cancer 89 (2003) 2197-2201
30. Roberts J.P., and Lurain J.R. Treatment of low risk metastatic gestational trophoblastic tumors with single agent chemotherapy. Am J Obstet Gynecol 174 (1996) 1917-1924
31. Abrao R.A., de Andrade J.M., Tiezzi D.G., et al. Treatment for low-risk gestational trophoblastic disease: comparison of single-agent methotrexate, dactinomycin and combination regimens. Gynecol Oncol 108 (2008) 149-153
32. Osborne R. A randomized phase III trial comparing weekly parenteral methotrexate and 'pulsed' dactinomycin as primary management for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. Presented at: the Annual Meeting on Women's Cancer, Society of Gynecologic Oncology, Tampa, FL, March 9-12, 2008.
33. Covens A., Filiaci V.L., Burger R.A., Osborne R., and Chen M.D. Phase II trial of pulse dactinomycin as salvage therapy for failed low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. Cancer 107 (2006) 1280-1286
34. Sharma S., Jagdev S., Coleman R.E., et al. Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis. Br J Cancer 81 (1999) 1037-1041
35. Homesley H.D., Blessing J.A., Rettenmaier M., et al. Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Obstet Gynecol 72 (1988) 413-418
36. Homesley H.D., Blessing J.A., Schlaerth J., et al. Rapid escalation of weekly intramuscular MTX for nonmetastatic gestational trophoblastic disease: a gynecologic oncology group study. Gynecol Oncol 39 (1990) 305-308
37. Lurain J.R., and Elfstrand E.P. Single agent methotrexate chemotherapy for the treatment of nonmetastatic trophoblastic tumors. Am J Obstet Gynecol 172 (1995) 574-579
38. Dubeshter B., Berkowitz R.S., Goldstein D.P., et al. Metastatic gestational trophoblastic disease: experience at the New England Trophoblastic Disease Center, 1965 to 1985. Obstet Gynecol 69 (1987) 390-395
39. Matsui H., Suzuka K., Yamazawa K., et al. Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy. Gynecol Oncol 96 (2005) 616-620
40. Chen Y.X., Shen Y.M., Qian J.H., et al. Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof. Zhonghua Yi Xue Za Zhi 85 (2005) 2109-2112
41. Kwon J.S., Elit L., Mazurka J., et al. Weekly intravenous methotrexate with folinic acid for nonmetastatic gestational trophoblastic neoplasia. Gynecol Oncol 82 (2001) 367-370
42. Yang J., Xiang Y., Wan X., et al. Recurrent gestational trophoblastic tumor: management and risk factors for recurrence. Gynecol Oncol 103 (2006) 587-590
43. Mutch D.G., Soper J.T., Babcock C.J., et al. Recurrent gestational trophoblastic disease. Cancer 66 (1990) 978-982